
Pfizer scientist claimed delay of COVID jab results until after 2020 election ‘wasn't a coincidence,' House GOP panel alleges
The House Judiciary Committee revealed Thursday that Pfizer's former Global Head of Vaccines Research and Development, Dr. Philip Dormitzer, may have 'conspired to withhold public health information to influence' the presidential contest between Donald Trump and Joe Biden.
5 he release of COVID-19 vaccine results days after the 2020 election may have not been a 'coincidence' — and could have been part of an effort by senior Pfizer executives to 'deliberately slow down' the testing, a House panel alleged.
frank – stock.adobe.com
The London-based drugmaker GSK in an April 16 letter to Judiciary Chairman Jim Jordan (R-Ohio) disclosed that Dormitzer 'approached a representative from the GSK human resources team to speak about a potential relocation abroad' in November 2024.
According to the HR rep, the ex-Pfizer vaccine scientist was 'visibly upset' in the meeting and asked to be moved to Canada 'due to concerns that he could be investigated by the incoming Trump Administration over his role in developing Pfizer's COVID-19 vaccine.'
When the GSK employee asked what his reasons were for requesting the relocation, Dormitzer apparently responded: 'Let's just say it wasn't a coincidence, the timing of the vaccine.'
5 'My Pfizer colleagues and I did everything we could to get the FDA's Emergency Use Authorization at the very first possible moment,' Dormitzer said in March in response to the allegations.
Bloomberg via Getty Images
Pfizer used independent experts to review the effectiveness and safety of its vaccines and broadcast the results being shared by its scientists just five days after polls closed for the 2020 election on Nov. 3.
GSK also divulged in the letter that some of its employees heard from the scientist 'in late 2020, the three most senior people in Pfizer R&D were involved in a decision to deliberately slow down clinical testing so that it would not be complete prior to the results of the presidential election that year.'
But the drugmaker, in its letter, also denied that Dormitzer was copping to 'delaying disclosure of completed results,' characterizing his statements as being part of 'a situation of slowing down results before disclosure became necessary.'
The Judiciary panel still fired off a pair of letters to Dormitzer and Pfizer's chairman and CEO, Dr. Albert Bourla, on Thursday demanding all records — including emails, texts, meeting notes and other documents — showing data from the clinical trials or communications with federal public health agencies.
5 The House Judiciary Committee revealed Thursday that the former head of Global Head of Vaccines Research and Development may have 'conspired to withhold public health information to influence' the 2020 election.
AP
'This new information appears to suggest that you and other senior Pfizer executives conspired to withhold public health information to influence the 2020 presidential election,' Jordan wrote to Dormitzer.
'Due to the seriousness of these allegations, the Committee is compelled to request additional information to inform our oversight.'
The responsive files are supposed to cover the period between March 2020 and the present, per the letters.
5 Dormitzer's comments to GSK employees were first made in the course of a federal probe by Manhattan prosecutors, which, along with the Judiciary letters, was first reported by The Wall Street Journal.
LightRocket via Getty Images
Jordan's panel has also demanded Dormitzer schedule a transcribed interview no later than May 29.
Dormitzer's comments to GSK employees were first made in the course of a federal probe by Manhattan prosecutors, which, along with the Judiciary letters, was first reported by The Wall Street Journal.
The scientist has denied that he or anyone at Pfizer tried to delay the vaccine, and said his comments to his colleagues at GSK were misinterpreted.
'My Pfizer colleagues and I did everything we could to get the FDA's Emergency Use Authorization at the very first possible moment,' Dormitzer previously told Reuters in a statement amid the investigation by the US Attorneys' Office for the Southern District of New York.
5 President Trump has touted how 'proud' he was of 'Operation Warp Speed' being able to get Americans vaccinated from COVID.
Getty Images
'Any other interpretation of my comments about the pace of the vaccine's development would be incorrect.'
'Pfizer is in receipt of the letter asking about allegations made in a Wall Street Journal story, and we will respond directly to the Committee,' a rep for the pharmaceutical company said in a statement.
'The COVID-19 vaccine development process was driven by science and guided by the U.S. FDA back in 2020,' the rep added.
'We have consistently and transparently reiterated the facts and the timeline of the tireless work of scientists, regulators, and thousands of clinical trial volunteers who made the vaccine possible. Theories to the contrary are simply untrue and being manufactured.'
Reps for GSK did not immediately respond to a request for comment.
President Trump has touted how 'proud' he was of 'Operation Warp Speed' being able to get Americans vaccinated from COVID, with the purchase of 200 million doses of Pfizer's vaccine and 200 million doses of the Moderna shot.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNBC
41 minutes ago
- CNBC
Astronomer hires Gwyneth Paltrow with a wink after 'kiss cam' viral video
Data company Astronomer may be making lemonade by hiring Gwyneth Paltrow as a "temporary spokesperson" to answer questions in the wake of a viral "kiss cam" video. The company made headlines after internet sleuths identified its CEO and chief people officer as the man and woman seen embracing and then hiding their faces on a "kiss cam" at a July 16 Coldplay concert. Both have since resigned. Paltrow appeared in a television-style spot on Astronomer's social media on Friday making a pitch for the company's everyday strengths. "Astronomer has gotten a lot of questions over the last few days, and they wanted me to answer the most common ones," said Paltrow, who split with Coldplay singer Chris Martin in 2014. Paltrow cut off a question that started with "OMG!" to emphatically say, "Yes, Astronomer is the best place to run Apache Airflow." "We've been thrilled so many people have a newfound interest in data workflow automation," she added. She interrupted another question — "How is your social media team holding ..." — to make a pitch for an Astronomer conference in September. Paltrow concluded, "We will now be returning to what we do best — delivering game-changing results for our customers." CEO Andy Byron resigned on July 19, and Chief People Officer Kristin Cabot followed on Thursday, according to statements from the company. Their body language after the camera captured them in an embrace led Martin to remark on stage, "Either they're having an affair or they're just very shy." Astronomer said afterward it was investigating the incident. "Our leaders are expected to set the standard in both conduct and accountability," it said on July 18. The company confirmed Thursday that Cabot was the woman in the video. Neither she nor Byron have responded to requests for comment. Astronomer, a New York-based company, helps companies develop, grow, and analyze products using artificial intelligence.

Yahoo
an hour ago
- Yahoo
No Republican candidate yet for secondary Sunbury City Council election
SUNBURY — A Republican candidate for a secondary Sunbury City Council race in November has yet to be announced, according to the Northumberland County Election's Office. Each party has until Sept. 15 to name a candidate for the two-year seat, according to Northumberland County Director of Elections Lindsay Phillips. Northumberland County Democratic Committee Chairperson, John J. Merchlinsky III, announced the Democratic committee chose Victoria Rosancrans as their candidate. The seat became open when former Councilwoman Lisa Martina resigned to become city treasurer. Merchlinsky said Rosancrans is a longtime community leader and advocate who would bring three decades of volunteer service and proven leadership to the position. The secondary election came to be after Martina ran for and won the Republican nomination for city treasurer in May. She is unopposed for the November General Election. She was appointed to fill the vacancy left when former Treasurer Kevin Troup retired to pursue a seat on city council. Martina stepped down from from city council after she was appointed treasurer. Troup, current Councilman Nate Savidge and Andres Manresa all advanced out of the primary and will be competing for two four-year seats on council. The secondary election was announced by the Northumberland County Election's Office last month. Northumberland County Republican Chairperson Deb Betz could not be reached for comment. Sunbury City Council members John Barnhart, Jim Eister, Savidge and Mayor Josh Brosious are waiting for a decision from Northumberland County president Judge Paige Rosini on who will fill the vacant seat until January. Solicitor Joel Wiest filed a petition to the court after council could not agree on an appointment for the seat. The two candidates that were voted on at a council meeting nearly two weeks ago were Rosancrans and city resident Andrew Ramos. Both received two votes, and council decided to petition the court to fill the vacancy. Rosini does not have to choose between the two, and can appoint anyone she wants to fill the seat. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@